Ximelagatran increased quality-adjusted survival by 0.12 QALYs compared with warfarin but at a substantial cost of $116,000 per QALY in patients with additional stroke risk factors.
Does ximelagatran improve quality-adjusted survival and cost-effectiveness compared with warfarin and aspirin in 70-year-old patients with chronic atrial fibrillation?
Ximelagatran is unlikely to be cost-effective compared to warfarin for stroke prophylaxis in atrial fibrillation unless patients have a high risk of intracranial hemorrhage or low quality of life on warfarin.
CONTEXT: Recent trials have found that ximelagatran and warfarin are equally effective in stroke prevention for patients with atrial fibrillation. Because ximelagatran can be taken in a fixed, oral dose without international normalized ratio monitoring and may have a lower risk of hemorrhage, it might improve quality-adjusted survival compared with dose-adjusted warfarin. OBJECTIVE: To compare quality-adjusted survival and cost among 3 alternative therapies for patients with chronic atrial fibrillation: ximelagatran, warfarin, and aspirin. DESIGN: Semi-Markov decision model. PATIENTS: Hypothetical cohort of 70-year-old patients with chronic atrial fibrillation, varying risk of stroke, and no contraindications to anticoagulation therapy. MAIN OUTCOME MEASURES: Quality-adjusted life-years (QALYs) and costs in US dollars. RESULTS: For patients with atrial fibrillation but no additional risk factors for stroke, both ximelagatran and warfarin cost more than 50,000 dollars per QALY compared with aspirin. For patients with additional stroke risk factors and low hemorrhage risk, ximelagatran modestly increased quality-adjusted survival (0.12 QALY) at a substantial cost (116,000 dollars per QALY) compared with warfarin. For ximelagatran to cost less than 50,000 dollars per QALY it would have to cost less than 1100 dollars per year or be prescribed to patients who have an elevated risk of intracranial hemorrhage (>1.0% per year of warfarin) or a low quality of life with warfarin therapy. CONCLUSION: Assuming equal effectiveness in stroke prevention and decreased hemorrhage risk, ximelagatran is not likely to be cost-effective in patients with atrial fibrillation unless they have a high risk of intracranial hemorrhage or a low quality of life with warfarin.
Cara O’Brien (Tue,) conducted a other in Chronic atrial fibrillation. Ximelagatran vs. Warfarin and aspirin was evaluated on Quality-adjusted life-years (QALYs) and costs in US dollars. Ximelagatran increased quality-adjusted survival by 0.12 QALYs compared with warfarin but at a substantial cost of $116,000 per QALY in patients with additional stroke risk factors.